What are the benefits of using fasenra for eosinophilic asthma?

What makes Fasenra different from other asthma treatments?

Fasenra contains benralizumab, an antibody that targets eosinophils, the immune cells that drive inflammation in eosinophilic asthma. It binds to the IL-5 receptor on eosinophils and depletes them almost completely. This is different from inhaled corticosteroids or long-term beta agonists that only control symptoms.

How does Fasenra improve breathing and reduce attacks?

Patients who use Fasenra see fewer asthma attacks. Clinical studies show it cuts exacerbations by half compared with placebo. The drug also improves lung function, measured by FEV1, and allows some patients to reduce their oral steroid dose.

Does Fasenra help patients who are oral-steroid dependent?

Yes. In the SIROCCO and CALIMA trials, Fasenra enabled many patients to lower or stop oral steroids while keeping asthma under control. This avoids long-term steroid side effects such as osteoporosis, diabetes, and weight gain.

What side effects do patients report?

The most common reactions are headache and sore throat. Pharyngitis occurs in a few percent of users. Rare cases of hypersensitivity and helminth infections have been reported. Patients must watch for signs of parasitic infection if they travel to endemic areas.

How long does it take to work?

Eosinophil counts drop sharply after the first injection. Asthma improvements show up within weeks, but full clinical effect often erstreckt four to eight weeks.

What happens if a patient stops taking Fasenra?

Eosinophil levels rebound quickly after discontinuation. Asthma symptoms and attacks can return within months. The drug is meant for long-term maintenance rather than a brief treatment course.

Why are companies challenging this patent?

Generic manufacturers and competitors have filed challenges against Fasenra's patents. They seek early entry into the market before the main patent expires in 2030.